Shares of e-therapeutics plc (LON:ETX – Get Free Report) fell 6.7% on Thursday . The stock traded as low as GBX 9 ($0.11) and last traded at GBX 9 ($0.11). 2,518,125 shares were traded during trading, an increase of 232% from the average session volume of 758,869 shares. The stock had previously closed at GBX 9.65 ($0.12).
e-therapeutics Stock Performance
The company has a quick ratio of 20.13, a current ratio of 22.20 and a debt-to-equity ratio of 0.33. The stock has a fifty day moving average of GBX 11.18 and a 200-day moving average of GBX 11.74. The firm has a market capitalization of £52.59 million, a P/E ratio of -450.00 and a beta of 0.48.
About e-therapeutics
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
Read More
- Five stocks we like better than e-therapeutics
- What is the Hang Seng index?
- Roblox: The Bottom Just Fell Out of the Metaverse
- ESG Stocks, What Investors Should Know
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- How to Invest in Small Cap Stocks
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
